Table 1.
Baseline estimates for selected variables
| Variable | Baseline value | Range | Reference |
|---|---|---|---|
| Prevalence of H. pylori infection | |||
| Aged 20 years | 0.048 | 0.01–0.1 | 19 |
| Aged 30 years | 0.180 | 0.01–0.2 | Assumption |
| Aged 40 years | 0.229 | 0.01–0.3 | |
| Aged 50 years | 0.374 | 0.01–0.4 | |
| Aged 60 years | 0.461 | 0.01–0.6 | |
| Sensitivity of HPA | 0.88 | 0.85–0.96 | 26 |
| Specificity of HPA | 0.96 | 0.95–0.97 | 26 |
| Hospital approach rate for H. pylori eradication treatment | 0.75 | 0.2–1 | Assumption |
| Efficacy of H. pylori eradication treatment | 0.8 | 0.70–0.86 | 20 |
| Gastric cancer rate with H. pylori infection | 0.029 | 0.0016–0.0625 | 23, 24 |
| Gastric cancer rate after successful eradication | 0.0047 | 0.0012–0.0047 | 23, 24 |
| Gastric cancer rate without H. pylori infection | 0.0001 | 0.00006–0.0007 | 25 |
| Mortality rate of gastric cancer | 0.03 | 0.01–0.17 | 22 |
| Costs (US$1 = ¥108.8) | |||
| HPA | 9.2 | 4.6–18.4 | 18 |
| H. pylori eradication treatment | 210 | 105–420 | |
| Endoscopic screening with urea breath test for diagnosis of H. pylori infection | 316 | 158–632 | |
| Gastric cancer treatment | 2390 | 1195–4780 | |
| Utilities | |||
| No H. pylori infection | 1 | – | 17 |
| H. pylori infection | 0.90 | 0.77–0.99 | |
| Gastric cancer | 0.68 | 0.55–0.81 | |
| Dead | 0 | – |
HPA, H. pylori antibody test; H. pylori, Helicobacter pylori.